Type 2 Diabetes Clinical Trial
— TODOfficial title:
Family-Based, Culturally-Centered Diabetes Intervention With Ojibwe Communities
Verified date | April 2024 |
Source | Johns Hopkins Bloomberg School of Public Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Together Overcoming Diabetes (TOD) is a culturally tailored, family-based type 2 diabetes management and preventive intervention. Participants in this trial are American Indian adult caregivers diagnosed with type 2 diabetes and their youth, aged 10-16 years at enrollment. Adult/youth participant dyads will be enrolled across 5 Ojibwe tribal communities. Consenting participant dyads will be randomized into one of two groups: Group A: begin the intervention program immediately; Group B (waitlist): begin the intervention program in 2 years. Both groups will complete assessments with study staff at baseline, 3, 6, 12, 18, and 24 months to assess HbA1c, cholesterol, blood pressure (adults), biometric measures, and psychosocial and behavioral outcomes (adults and youth). The 14-lesson intervention program will be delivered in the participant's home by local Family Health Coaches over a 6-month period. Upon completion of the intervention, participants may also be invited to participate in a "Ripple Effects Mapping" (REM) session for discussions, and mapping of the intervention effects.
Status | Active, not recruiting |
Enrollment | 162 |
Est. completion date | June 1, 2026 |
Est. primary completion date | April 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years and older |
Eligibility | Inclusion Criteria: ADULT (target participants) - Are greater than 18 years of age - Self-identify as American Indian - Have a completed verification form from a healthcare provider indicating a confirmed diagnosis of type 2 diabetes - Live on or within 30 miles of participating reservations - Are a caregiver to a 10-16 year-old who lives in their home - Are willing to be randomly put into Group A (intervention) or Group B (waitlist control) - Are willing to complete all lessons and assessments - Speak and read English - Are not cognitively or visually impaired (able to review and sign informed consent and complete assessments) YOUTH - 10 -16 years of age - Self-identify as American Indian - Live with an adult who has joined the study - Are willing to be randomly put into Group A or Group B - Are willing to complete all lessons and assessments - Speak and read English - Are not cognitively or visually impaired (able to review and sign informed consent and complete assessments) Exclusion Criteria: ADULTS (target participants) - Are not American Indian - No confirmed type 2 diabetes diagnosis - Not a caregiver to a youth ages 10-16 in their home - Does not live within the distance inclusion criteria - Is unable to complete the study procedures - Has comorbidity(ies) that may have an impact on type 2 diabetes management YOUTH - Are not American Indian - Do not fall within the specified age range of 10-16 years at time of enrollment - Do not have an enrolled Adult caregiver - Unable to read and speak English - Not willing to complete the study procedures |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins University Great Lakes Hub | Duluth | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins Bloomberg School of Public Health | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Physical Activity - Adult and Youth participants | Survey questions will ask about physical activity duration, frequency, intensity. Higher score equates to better outcome. | Day 0, Month 6, Month 12, and Month 24 | |
Other | Change in Communal Mastery - Adult and Youth participants | Communal Mastery as a Coping Resource. Scoring ranges from 0 to 3. Higher score equates to better outcome. | Day 0, Month 6, Month 12, and Month 24 | |
Other | Change in Diabetes Empowerment - Adult participants | Diabetes Empowerment Scale (short form, Anderson, et al., 2003). Scoring ranges from 0 to 3. Higher score equates to better outcome. | Day 0, Month 6, Month 12, and Month 24 | |
Primary | Change in Adult Participant Fasting HbA1c | Change in hemoglobin A1c | Day 0, Month 3, Month 6, Month 12, Month 18, and Month 24 | |
Secondary | Change in BMI/zBMI - Adult and Youth participants | zBMI change as indication of weight loss | Day 0, Month 3, Month 6, Month 12, Month 18, and Month 24 | |
Secondary | Change in Depression and Depressive symptoms - Adult and Youth participants | Patient Health Questionnaire (PHQ-9) Adult and Adolescent versions. Scoring ranges from 0 to 3. Higher total score equates to worse outcome. | Day 0, Month 3, Month 6, Month 12, Month 18, and Month 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |